Enanta Pharmaceuticals (ENTA) Net Margin (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted Net Margin of 76.29% for Q1 2026, down 18.96% on a QoQ basis from 64.13% in Q4 2025, and up 7542.0% year-over-year from 1.0% in Q1 2025.
Enanta Pharmaceuticals (ENTA) Net Margin (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals' Net Margin history runs 15 years deep, the most recent figure standing at 76.29% for Q1 2026.
- Quarterly Net Margin rose 7542.0% year-over-year to 76.29% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 89.56% (up 6001.0% YoY) and the FY2025 annual result came in at 125.36%, up 4622.0% from the prior year.
- Net Margin was 76.29% for Q1 2026 at Enanta Pharmaceuticals, down from 64.13% in the prior quarter.
- Across five years, Net Margin topped out at 64.13% in Q4 2025 and bottomed at 211.62% in Q1 2023.
- A 5-year average of 146.29% and a median of 135.14% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin surged 21773 bps — and 2023, when it sank 6266 bps.
- Enanta Pharmaceuticals' Net Margin stood at 122.9% in 2022, then slumped by 51 bps to 185.56% in 2023, then grew by 29 bps to 131.43% in 2024, then soared by 51 bps to 64.13% in 2025, then dropped by 19 bps to 76.29% in 2026.
- Business Quant data shows ENTA's Net Margin at 76.29% in Q1 2026, 64.13% in Q4 2025, and 123.64% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 376.07 Mn | 212.29 Mn | - | -76.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76.29% |
| Dec 31, 2025 | -64.13% |
| Sep 30, 2025 | -123.64% |
| Jun 30, 2025 | -99.68% |
| Mar 31, 2025 | -151.71% |
| Dec 31, 2024 | -131.43% |
| Sep 30, 2024 | -197.32% |
| Jun 30, 2024 | -126.08% |
| Mar 31, 2024 | -182.70% |
| Dec 31, 2023 | -185.56% |
| Sep 30, 2023 | -135.14% |
| Jun 30, 2023 | -206.78% |
| Mar 31, 2023 | -211.62% |
| Dec 31, 2022 | -122.90% |
| Sep 30, 2022 | -129.68% |
| Jun 30, 2022 | -162.74% |
| Mar 31, 2022 | -179.48% |
| Dec 31, 2021 | -108.92% |
| Sep 30, 2021 | -347.41% |
| Jun 30, 2021 | -111.10% |